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Background: Maspin is a 42 kDa protein known to act as a tumor suppressor. Although its function has not been
fully elucidated, numerous reports have investigated the prognostic impact of maspin in patients with several types
of cancer. However, there have been no reports on the association between maspin expression and the prognosis
of patients with soft tissue sarcomas (STS). The aim of this study was thus to explore the association of maspin
expression with the prognosis of patients with STS.
Methods: One-hundred and eight paraffin-embedded STS tissue samples were immunohistochemically analyzed
using antibodies for maspin and Ki-67 antigen. The patients were followed up for 1 to 300 months (median:
33 months) and the prognostic value was evaluated by log-rank test and Cox’s regression hazard model.
Results: Cytoplasmic maspin expression was observed in 48.1% of specimens, and was significantly correlated with
a higher FNCLCC grade (P = 0.002) and the presence of distant metastases (P = 0.001), and those with cytoplasmic
maspin expression had both shorter disease-free survival (DFS) and overall survival (OS) by log-rank test (P <0.001,
P = 0.001, respectively). By Cox’s multivariate analysis, the presence of distant metastases was the only prognostic
factor for DFS and OS.
Conclusions: This is the first report to reveal an association between maspin expression and the prognosis of
patients with STS. Although further studies with a larger series of patients and a longer follow-up period will be
needed, cytoplasmic maspin expression could be an indicator of unfavorable prognosis in patients with STS.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/13000_2014_205
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Soft tissue sarcomas (STS) are relatively rare malignant
mesenchymal tumors and constitute less than 1.5% of all
cancers, with an annual incidence of about 6 per
100,000 persons [1]. Except for a few types of sarcomas,
histological typing does not provide sufficient informa-
tion for predicting the clinical course of the disease [2].
Therefore, grading and staging systems have been used
to predict prognosis and to decide on treatment strat-
egies for adult patients with STS. Several reports have
described the relationship between the grading system* Correspondence: yume@med.tottori-u.ac.jp
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unless otherwise stated.and prognosis of adult patients with STS, and it has
been suggested that the histological grade is the most
important prognostic factor [3,4]. In addition, the Ki-67
labeling index has also been reported to be a useful pre-
dictor for the prognosis in STS patients [5]. Maspin
(mammary serine protease inhibitor) is a 42 kDa protein
known to act as a tumor suppressor, and is a member of
the serine protease inhibitor (serpin) superfamily. Mas-
pin has been shown to inhibit both tumor growth and
metastasis in multiple animal models and cancer cell
lines [6]. Although the function of maspin has not been
fully elucidated, many reports have described the asso-
ciation between maspin expression and clinicopathologi-
cal factors in several types of cancer such as breast,
prostate, gastric, pancreatic, gallbladder, colorectal, andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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also reported an association between maspin expression
and clinicopathological factors in several types of cancer
such as breast cancer [8-10], colorectal cancer [11], en-
dometrioid endometrial carcinoma [12] and ovarian mu-
cinous borderline tumor [13], and have suggested that
cytoplasmic maspin expression may be an indicator of
poor prognosis. Although only two reports have described
maspin expression in STS [14,15], to our knowledge, no
reports have investigated the association between maspin
expression and the prognosis of patients with STS. The
aim of this study was thus to investigate whether cytoplas-




All STS tissue specimens were obtained from the De-
partment of Pathology, Tottori University Hospital, and
the affiliated teaching hospitals. We obtained 108 speci-
mens from 108 patients who underwent surgery between
October 1981 to March 2012. The specimens consisted
of 94 primary tumors, 8 recurrent tumors, and 6 meta-
static tumors. Information about adjuvant therapy was
obtained for 99 of the patients. Neoadjuvant and/or ad-
juvant chemotherapy were performed in 22 patients,
neoadjuvant and/or adjuvant radiotherapy in 23 patients,
and both therapies in 22 patients. We also obtained cli-
nical data such as age, gender, tumor localization, tumor
size, presence of distant metastases, methods of treat-
ment, and clinical outcome. The median follow-up
period was 33 months (range: 1–300 months). A histo-
logical diagnosis was established according to the
World Health Organization classification [2]. Histo-
logical grades were assigned according to the French
Federation of the Cancer Center Sarcoma Group
(FNCLCC) system. Written informed consent was ob-
tained and the present study was performed with the
approval of the Ethics Committee of the Faculty of
Medicine, Tottori University (No. 1558).
Immunohistochemical procedures
All specimens were fixed in 10% buffered formalin and
embedded in paraffin wax. After the sections (4 μm-
thick) were deparaffinized and endogenous peroxidase
activity was blocked, they were pretreated in citrate buf-
fer (0.01 M, pH 6.0) using a microwave oven (RE-DD6-
S; Sharp Corporation, Osaka, Japan) for 20 minutes.
After cooling to room temperature, the sections were in-
cubated at 4°C overnight with the following primary
antibodies: monoclonal anti-human maspin antibody
(clone EAW24; diluted 1:150; Leica Biosystems, Newcas-
tle Ltd., UK), and mouse monoclonal anti-Ki-67 anti-
body (MIB-1; diluted 1:50; Dako, Glostrup, Denmark).The sections were incubated with biotinylated anti-mouse
IgG antibody (BA-2000; diluted 1:150; Vector Laborator-
ies, Burlingame, VT) for 20 minutes, followed by streptavi-
din biotinylated-HRP conjugate (diluted 1:150; Invitrogen
Corporation, Camarillo, CA) for 20 minutes. The sections
were then incubated with DAB solution (Liquid DAB+
Substrate, Imidazole-HCl buffer, pH 7.5, containing hydro-
gen peroxide and an anti-microbial agent; Dako, Glostrup,
Denmark) for 4 minutes, and finally counterstained with
hematoxylin. Normal mammary tissue specimens were
used as positive controls for maspin expression.Evaluation of immunohistochemical findings
The cells were considered positive cells for maspin ex-
pression only when cytoplasmic staining was identified.
To count the number of positive cells, a 10 × 10 square
grid in the eye-piece was used. The sections were
scanned at low and high power magnifications covering
all fields. At least three areas having the highest degree
of positive cells were selected, and typically 400–500
tumor cells in each field were counted irrespective of
immunoreactive status. Thereafter, positive cells were
counted and the positive ratio was determined. Tumors
with more than 10% positive cells were considered posi-
tive for the expression of maspin. We observed Ki-67-
positive cell nuclei by a CCD camera in the most dis-
tinctly labeled area to evaluate Ki-67 expression. Counts
were performed using high-magnification fields with the
FLOVEL Image Filing System FlvFs (FLOVEL Inc.,
Tachikawa, Japan). For measurement of Ki-67 expres-
sion, a minimum of 1,000 tumor cells were counted, and
the labeling index was determined by calculating the
number of positive cells as a percentage of total cells.
These evaluations were performed independently by two
authors (C.T. and Y.U.) who were blinded to the patient
outcome data.Statistical analysis
Statistical analysis was performed using the Statistical
Package for Social Sciences version 21 (IBM SPSS Statis-
tics; IBM Corporation, New York, NY). The association
between maspin expression and clinicopathological pa-
rameters was evaluated by non-parametric tests. The
Mann–Whitney U test and Chi-square test were used
when there were two categorical variables of interest and
the Kruskal-Wallis test when there were three variables.
Survival curves were calculated using the Kaplan-Meier
method and compared by the log-rank test. Multivariate
analysis was performed using the Cox proportional
hazards regression model and the backward selection
method. Hazard ratios were reported with 95% confi-
dence intervals (CI). Values of P <0.05 were considered
to be statistically significant.
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Clinicopathological features
Table 1 shows the characteristics of the 108 patients
with STS. The majority of patients were adults, with a
mean age of 58.3 years (range: 4–93 years). 53 patients
were <60 years, and 55 were ≥60 years; 65 patients were
male and 43 female. There were 29 tumors <5 cm and
79 tumors were ≥5 cm. There were 88 tumors located in
the extremities, 18 in the trunk, and 2 in other areas.
Distant metastases were absent in 71 patients and
present in the remaining 37 patients. Tumors of FNCLCC
grades 1, 2, and 3 were identified in 28, 48, and 32 patients,
respectively. The tumors consisted of 39 leiomyosarcomas,
34 liposarcomas, 15 synovial sarcomas, 8 myxofibrosarco-
mas, 6 undifferentiated/unclassified sarcomas, 5 epitheli-
oid sarcomas and 1 rhabdomyosarcoma. The 8 recurrent
tumors consisted of 4 leiomyosarcomas, 2 liposarcomas,
and 2 undifferentiated/unclassified sarcomas, and the 6
metastatic tumors consisted of 4 leiomyosarcomas, 1 lipo-
sarcoma, and 1 rhabdomyosarcoma.Table 1 Association between maspin expression and
clinicopathological variables in 108 soft tissue sarcomas
Maspin expression
Charactaristics Positive Negative P-value
52 cases 56 cases
Age
< 60 years 21 32 0.061
≥ 60 years 31 24
Gender
Male 33 32 0.318
Female 19 24
Tumor size
< 5 cm 15 14 0.407
≥ 5 cm 37 42
Tumor localization




Absent 26 45 0.001
Present 26 11
FNCLCC grade




< 10% 32 43 0.065
≥ 10% 20 13Immunohistochemical findings
The mean Ki-67 labeling index of all STS specimens
was 8.76 ± 9.77%; 75 cases were labeled <10%, and 33
cases were labeled ≥10% Ki-67 positive. Maspin ex-
pression was observed only in the cytoplasm in 52
specimens, in both the cytoplasm and nucleus in 15
specimens, only in the nucleus in 11 specimens, and
not at all in 30 specimens; 48.1% of STS specimens
were judged to be maspin-positive. By histological
type, the number and proportion of maspin positive
cases were 22 (56.4%), 8 (23.5%), 11 (73.3%), 2
(25.0%), 4 (66.7%), and 5 (100%) for leiomyosarcoma,
liposarcoma, synovial sarcoma, myxofibrosarcoma,
undifferentiated/unclassified sarcoma, epithelioid sar-
coma, and rhabdomyosarcoma, respectively. The de-
tails of maspin expression by histological type are
shown in Table 2. Representative images of maspin
staining are shown in Figure 1 for a leiomyosarcoma,
liposarcoma, myxofibrosarcoma, and epithelioid sarcoma.Correlation between maspin expression and
clinicopathological factors
Cytoplasmic maspin expression was significantly corre-
lated with distant metastases (P = 0.001) and FNCLCC
grade (P = 0.002). With respect to the FNCLCC grades,
a significant correlation was observed between grade 1
and grade 3 (P <0.01). Other clinicopathological factor,
including age, gender, tumor location and size, and Ki-
67 labeling showed no significant correlation with cyto-
plasmic maspin expression.Table 2 Maspin expression in 108 soft tissue sarcomas
Histologic type Maspin expression
Positive (%) Negative
52 (48.1) 56
Leiomyosarcoma 22 (56.4) 17
Liposarcoma 8 (23.5) 26
Well-differentiated 5 (29.4) 12
Myxoid 2 (14.3) 12
Pleomorphic 1 (50) 1
Dedifferentiated 0 1
Synovial sarcoma 11 (73.3) 4
Spindle cell 6 (85.7) 1
Biphasic 5 (62.5) 3
Myxofibrosarcoma 2 (25) 6
Undifferentiated/ unclassified sarcoma 4 (66.7) 2
Epithelioid sarcoma 5 (100) 0
Rhabdomyosarcoma 0 1
Embryonal 0 1
Figure 1 Representative maspin immunoreactivity in a leiomyosarcoma (A), liposarcoma (B), myxofibrosarcoma (C) and epithelioid
sarcoma (D). (original magnification, ×400).
Takeda et al. Diagnostic Pathology 2014, 19:205 Page 4 of 7
http://www.diagnosticpathology.org/content/19/1/205Survival analysis
After the follow-up period, 29 patients had died of STS
and 7 patients had died of other causes. Of the
remaining 72 patients, 12 patients experienced recur-
rence of STS. We excluded 17 patients with well-
differentiated liposarcomas from the survival analysis
due to their being classified as having intermediate, not
malignant, tumors; of these patients, 15 were still alive
and two had died of other causes. Maspin expression in
only cytoplasm was observed in 47 specimens, both in
cytoplasm and nucleus in 12 specimens, in only nucleus
in 8 specimens, and not at all in 24 specimens. Of the
91 patients analyzed by log-rank test, the patients who
were only cytoplasmic expression of maspin showed
shorter overall survival (OS) and disease-free survival
(DFS) (P = 0.001, P <0.001, respectively; Figure 2). Uni-
variate analysis showed a significant difference in both
DFS and OS according to FNCLCC grade (P = 0.015,
P = 0.016), distant metastases (P <0.001, P <0.001), Ki-
67 labeling index (P = 0.016, P = 0.031), and the
presence of maspin expression (P = 0.013, P =0.016), re-
spectively. By Cox multivariate analysis, the presence of
distant metastases was the only independent prognostic
indicator of both DFS and OS (P <0.001, P <0.001, re-
spectively; Table 3).
Discussion
Maspin is a member of the serpin family of protease in-
hibitors and was originally thought to be a tumor sup-
pressor due to its ability to inhibit invasion, motility, and
metastasis of mammary tumors [16]. However, loss ofmaspin expression in several cancers, such as pancreatic,
colorectal and ovarian cancer, is not commonly observed
due to a lack of maspin expression in the corresponding
normal tissue. The most compelling data regarding the
clinical significance of maspin in cancer progression and
metastasis emerged from survival studies of cancer pa-
tients. Although the original studies revealed an associ-
ation between reduced maspin expression and cancer
progression and worse prognosis, it has been demon-
strated that this correlation was far more complex than
originally suspected. Factors contributing to this com-
plexity include the differences in cancer type (e.g. adeno-
carcinoma vs squamous cell carcinoma), cut-off values
of positive criteria, antibodies used, methods of detec-
tion, and subcellular maspin distribution. The subcellu-
lar localization of maspin is predominantly cytoplasmic;
however, maspin exerts its effect in the nucleus at the
level of gene and chromatin regulation, and is released
only as a consequence of cell damage or necrosis [17,18].
Goulet et al. demonstrated that nuclear localization of
maspin was essential for its inhibition of tumor growth
and metastasis [19]. Sood et al. reported that nuclear
maspin staining was associated with increased survival,
whereas cytoplasmic maspin staining was associated with
a poor outcome in ovarian carcinoma [20]. Additionally,
Marioni et al. reported that nuclear maspin expression
was associated with a lower recurrence rate and a longer
disease-free interval after surgery for squamous cell car-
cinoma of the larynx [21]. We have also reported that
cytoplasmic maspin expression was associated with an ag-
gressive phenotype and poor prognosis of patients with
A 
B 
Figure 2 Disease-free survival (A) and overall survival (B) curves of 91 patients with soft tissue sarcomas according to maspin
expression status.
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trioid endometrial carcinoma [12]. On the other hand,
there have been few reports investigating maspin expres-
sion in non-epithelial tissue [22], and only two reports
have described the expression of maspin in STS. Kim et al.reported a case of metastatic leiomyosarcoma from a
uterus showing expression of maspin in addition to several
types of growth factors, angiogenic factors, and prolifera-
tive markers in the metastatic tumor cells by immunohis-
tochemistry and immunoblot detection [14]. Although
Table 3 Multivariate analysis of clinicopathological
factors for disease-free survival and overall survival in 91
soft tissue sarcomas
Variables Disease-free survival Overall survival
HR 95% CI P-
value
HR 95% CI P-
value
FNCLCC grade
III vs I,II 1.05 0.533-2.066 0.891 0.82 0.387-1.751 0.614
Distant metastasis
Present vs absent 12.7 5.682-27.78 < 0.001 55.6 7.575-500 < 0.001
Ki-67 labelling
index




1.53 0.777-3.005 0.219 1.64 0.708-3.791 0.248
HR, Hazard ratio; 95% CI, 95% confidence intervals.
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expression, they revealed that the maspin protein was
more intensely expressed in the metastatic tumor com-
pared to the primary uterine leiomyosarcoma. In the
present study, we observed the expression of maspin in
56.4% of leiomyosarcomas. These results highlight the
need for further studies on the use of maspin expression
as a prognostic indicator in leiomyosarcomas. Fitzgerald
et al. reported that chondrosarcoma cells exhibited upreg-
ulated maspin mRNA expression in addition to decreased
DNA methylation of the maspin gene [15]. They also dem-
onstrated that the upregulation of maspin mRNA may ei-
ther play an important role in malignant progression, or
simply be a biomarker of tumor progression. Their find-
ings may support our present results that expression of
maspin is correlated with the poor prognosis of patients
with STS, although chondrosarcomas were not investi-
gated in our study.
Conclusion
In conclusion, to our knowledge, this is the first report
investigating the association of maspin expression with
the prognosis of patients with STS. Although further
studies with a larger series of patients and a longer
follow-up period should be requisite, the present study
suggests the potential usefulness of cytoplasmic maspin
expression as a prognostic factor of patients with STS.
Further carefully designed studies will be needed to elu-
cidate the function and role of cytoplasmic maspin ex-
pression in patients with STS.
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